Amendment of Capital clause in the Memorandum of Association pursuant to proposed increase in the Authorized Capital
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech's board approved increasing the company's authorized share capital to Rs. 85 crore (8.5 crore equity shares of Rs. 10 each), amending the Capital Clause of the Memorandum of Association accordingly. The board also approved the disinvestment from material subsidiary Dindigul Farm Product Limited (DFPL), which contributed Rs. 6,282.81 lakhs (47.11%) to consolidated turnover and Rs. 3,521.13 lakhs (35.24%) to consolidated net worth for FY25. Several related party transactions of up to Rs. 25 crore each were approved with subsidiaries including Matrix Boilers, HSL Agri Solutions, HSLPrime Properties, IBL Investments and IBL Healthcare. The 33rd AGM is scheduled for 29th September 2025, with e-voting cut-off date of 22nd September 2025. Multiple director appointments, re-appointments and an Independent Director were also approved.
The authorized capital hike creates room for future fundraising or stock issuance, while the proposed disinvestment of DFPL – a major contributor to consolidated revenue and net worth – signals a significant restructuring that could materially affect future financials. Shareholders should watch for the terms and consideration of the DFPL divestment and the outcome of the AGM resolutions.